AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
266.69B
Market cap266.69B
Price-Earnings ratio
25.61
Price-Earnings ratio25.61
Dividend yield
1.83%
Dividend yield1.83%
Average volume
2.82M
Average volume2.82M
High today
$176.85
High today$176.85
Low today
$171.42
Low today$171.42
Open price
$175.37
Open price$175.37
Volume
3.60M
Volume3.60M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$137.23
52 Week low$137.23

Stock Snapshot

The current AstraZeneca(AZN) stock price is $169.01, with a market capitalization of 266.69B. The stock trades at a price-to-earnings (P/E) ratio of 25.61 and offers a dividend yield of 1.83%.

As of 2026-07-13, AstraZeneca(AZN) stock has fluctuated between $171.42 and $176.85. The current price stands at $169.01, placing the stock -1.4% above today's low and -4.4% off the high.

The AstraZeneca(AZN)'s current trading volume is 3.6M, compared to an average daily volume of 2.82M.

During the past year, AstraZeneca(AZN) stock moved between $137.23 at its lowest and $212.71 at its peak.

During the past year, AstraZeneca(AZN) stock moved between $137.23 at its lowest and $212.71 at its peak.

AZN News

TipRanks 1h
AstraZeneca downgraded to Hold from Buy at HSBC

HSBC analyst Rajesh Kumar downgraded AstraZeneca (AZN) to Hold from Buy with a price target of 13,750 GBp, down from 16,500 GBp. The firm says the company’s pat...

Financial Times 1d
AstraZeneca CEO: ‘Biology will catch up with me at some point’ - Financial Times

...

AstraZeneca CEO: ‘Biology will catch up with me at some point’ - Financial Times
Nasdaq 1d
AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage

Astrazeneca (NYSE:AZN) told investors and analysts that it is continuing to embed sustainability into its business strategy while updating some of its 2030 targ...

AstraZeneca Updates 2030 Sustainability Goals as AI and Emissions Cuts Take Center Stage

Analyst ratings

80%

of 30 ratings
Buy
80%
Hold
13.3%
Sell
6.7%

More AZN News

Nasdaq 3d
Astrazeneca Stock Dips While Market Gains: Key Facts

In the latest close session, Astrazeneca (AZN) was down 3.85% at $171.61. This move lagged the S&P 500's daily gain of 0.42%. Elsewhere, the Dow saw an upswing...

Astrazeneca Stock Dips While Market Gains: Key Facts
TipRanks 3d
SERAFA-1 Trial Update: AstraZeneca and Icon Deepen Their Breast Cancer Bet

Icon Plc (ICLR), AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with Ti...

TipRanks 3d
AstraZeneca’s Embold Trial Signals a Big Push Into the Obesity Drug Race

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium fo...

Nasdaq 3d
How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High

Shares of BridgeBio Pharma BBIO climbed to a 52-week high of $93.42 on Thursday after rival AstraZeneca's AZN late-stage clinical setback boosted investor confi...

How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High
TipRanks 3d
CSPC Receives US$25 Million R&D Milestone Payment from AstraZeneca

TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. R...

TipRanks 3d
Ionis Pharmaceuticals price target lowered to $95 from $110 at Canaccord

Canaccord analyst Gary Nachman lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $95 from $110 and keeps a Buy rating on the shares. The firm a...

TipRanks 4d
Ionis, AstraZeneca report Phase 3 eplontersen setback

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.